About this document

Alumis Inc. (ALMS) Buy Rating & $32 PT by frankypan2016 is a document available to read on EtoBox.

Guggenheim Securities initiates coverage of Alumis Inc. (ALMS) with a Buy rating and a price target of $32, focusing on its lead asset ESK-001, a next-gen TYK2 inhibitor in development for plaque psoriasis and systemic lupus erythematosus. ESK-001 is expected to enter Phase III trials in psoriasis in 2H24, with significant market potential estimated at $1.1B for psoriasis and $500MM for lupus. The report highlights the competitive advantages of ESK-001, including its pharmacological profile and safety, whil

Author

frankypan2016

Language

EN